108 related articles for article (PubMed ID: 38812359)
1. Correction to: Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer.
Cancer Sci; 2024 May; ():. PubMed ID: 38812359
[No Abstract] [Full Text] [Related]
2. Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer.
Lee MR; Woo SM; Kim MK; Han SS; Park SJ; Lee WJ; Lee DE; Choi SI; Choi W; Yoon KA; Chun JW; Kim YH; Kong SY
Cancer Sci; 2024 Apr; 115(4):1283-1295. PubMed ID: 38348576
[TBL] [Abstract][Full Text] [Related]
3. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
4. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
5. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.
Le Calvez-Kelm F; Foll M; Wozniak MB; Delhomme TM; Durand G; Chopard P; Pertesi M; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Vallee MP; Rinaldi S; Brennan P; McKay JD; Byrnes GB; Scelo G
Oncotarget; 2016 Nov; 7(48):78827-78840. PubMed ID: 27705932
[TBL] [Abstract][Full Text] [Related]
6. Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue.
Ako S; Nouso K; Kinugasa H; Dohi C; Matushita H; Mizukawa S; Muro S; Akimoto Y; Uchida D; Tomoda T; Matsumoto K; Horiguchi S; Tsutsumi K; Kato H; Okada H
Pancreatology; 2017; 17(2):285-290. PubMed ID: 28139399
[TBL] [Abstract][Full Text] [Related]
7. Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.
Brychta N; Krahn T; von Ahsen O
Clin Chem; 2016 Nov; 62(11):1482-1491. PubMed ID: 27591291
[TBL] [Abstract][Full Text] [Related]
8. New and potential clinical applications of KRAS as a cancer biomarker.
Kriegshäuser G; Auner V; Zeillinger R
Expert Opin Med Diagn; 2010 Sep; 4(5):383-95. PubMed ID: 23496197
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and Prognostic Values of KRAS Mutations on EUS-FNA Specimens and Circulating Tumor DNA in Patients With Pancreatic Cancer.
Wang R; Zhao Y; Wang Y; Zhao Z; Chen Q; Duan Y; Xiong S; Luan Z; Wang J; Cheng B
Clin Transl Gastroenterol; 2022 May; 13(5):e00487. PubMed ID: 35351843
[TBL] [Abstract][Full Text] [Related]
10.
Barzi A; Weipert CM; Espenschied CR; Raymond VM; Wang-Gillam A; Nezami MA; Gordon EJ; Mahadevan D; Mody K
Front Oncol; 2024; 14():1339302. PubMed ID: 38406801
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
[TBL] [Abstract][Full Text] [Related]
12. Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer.
Ako S; Kato H; Nouso K; Kinugasa H; Terasawa H; Matushita H; Takada S; Saragai Y; Mizukawa S; Muro S; Uchida D; Tomoda T; Matsumoto K; Horiguchi S; Nobuoka D; Yoshida R; Umeda Y; Yagi T; Okada H
Cancer Biol Ther; 2021 Dec; 22(10-12):564-570. PubMed ID: 34632919
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Circulating DNA to Assess Prognoses for Metastatic Colorectal Cancer Patients Treated with Regorafenib Dose-Escalation Therapy: A Retrospective, Exploratory Analysis of the RECC Trial.
Ohta R; Yamada T; Nakamura M; Enomoto M; Takahashi M; Yokomizo H; Kosugi C; Ishimaru K; Sonoda H; Kuramochi H; Yoshida Y; Furuya S; Hirata K; Yoshida H; Nozawa K; Hashiguchi Y; Ishida H; Koda K; Katsumata K; Sakamoto K
Digestion; 2023; 104(3):233-242. PubMed ID: 36646047
[TBL] [Abstract][Full Text] [Related]
14. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer.
Yang S; Che SP; Kurywchak P; Tavormina JL; Gansmo LB; Correa de Sampaio P; Tachezy M; Bockhorn M; Gebauer F; Haltom AR; Melo SA; LeBleu VS; Kalluri R
Cancer Biol Ther; 2017 Mar; 18(3):158-165. PubMed ID: 28121262
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer.
Schlick K; Markus S; Huemer F; Ratzinger L; Zaborsky N; Clemens H; Neureiter D; Neumayer B; Beate AS; Florian S; Martin V; Grundbichler M; Weiss L; Melchardt T; Greil R; Egle A
Pancreatology; 2021 Dec; 21(8):1466-1471. PubMed ID: 34511398
[TBL] [Abstract][Full Text] [Related]
16.
Garzón M; Villatoro S; Teixidó C; Mayo C; Martínez A; de Los Llanos Gil M; Viteri S; Morales-Espinosa D; Rosell R
Transl Lung Cancer Res; 2016 Oct; 5(5):511-516. PubMed ID: 27826532
[TBL] [Abstract][Full Text] [Related]
17. Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer.
Del Re M; Vivaldi C; Rofi E; Vasile E; Miccoli M; Caparello C; d'Arienzo PD; Fornaro L; Falcone A; Danesi R
Sci Rep; 2017 Aug; 7(1):7931. PubMed ID: 28801547
[TBL] [Abstract][Full Text] [Related]
18. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.
Cheng H; Luo G; Jin K; Fan Z; Huang Q; Gong Y; Xu J; Yu X; Liu C
Cancer Med; 2020 Mar; 9(6):2153-2159. PubMed ID: 32017404
[TBL] [Abstract][Full Text] [Related]
19. Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients.
Hosoya K; Matsusaka S; Kashiwada T; Suzuki K; Ureshino N; Sato A; Miki Y; Kitera K; Hirai M; Hatake K; Kimura S; Sueoka-Aragane N
Pathol Oncol Res; 2017 Oct; 23(4):737-744. PubMed ID: 28058585
[TBL] [Abstract][Full Text] [Related]
20.
Wang ZY; Ding XQ; Zhu H; Wang RX; Pan XR; Tong JH
Front Oncol; 2019; 9():1295. PubMed ID: 31850201
[No Abstract] [Full Text] [Related]
[Next] [New Search]
